Inovio Pharmaceuticals, Inc.
INO
Rank in Stocks
#19507
Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research,... Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is to prevent and cure illnesses associated with human papillomavirus (HPV), various types of cancer, and infectious diseases. The company's advanced DNA medicine platform utilizes meticulously engineered SynCon sequences to precisely identify and optimize the genetic blueprint of a target antigen. This innovative approach is supported by its CELLECTRA smart device technology, which efficiently delivers the DNA plasmids. Inovio is actively engaged in and planning clinical trials for its DNA medicines across a wide array of conditions. These include HPV-related precancerous lesions, such as cervical, vulvar, and anal dysplasia; HPV-driven cancers affecting areas like the head and neck, cervix, anus, penis, vulva, and vagina; and other HPV-associated disorders like recurrent respiratory papillomatosis. Beyond HPV, its pipeline addresses glioblastoma multiforme, prostate cancer, and a range of infectious diseases, including HIV, Ebola, Middle East Respiratory Syndrome (MERS), and Lassa fever. The company benefits from a vast network of collaborators and partners, encompassing prominent academic institutions, government agencies, non-profit foundations, and pharmaceutical corporations. Key examples include AstraZeneca, The Bill & Melinda Gates Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI), the Defense Advanced Research Projects Agency (DARPA), the National Institutes of Health, Regeneron Pharmaceuticals, and the University of Pennsylvania. Significant partnerships also involve an agreement with Richter-Helm BioLogics GmbH & Co. KG to further develop the investigational COVID-19 DNA vaccine INO-4800, alongside a strategic alliance with the International Vaccine Institute and Seoul National University Hospital. Established in 1979, Inovio Pharmaceuticals is headquartered in Plymouth Meeting, Pennsylvania.
Share Price
$1.51
Last synced: 2026-11-09
Market Cap
$104.33M
Change (1 day)
24.28%
Change (1 year)
-22.96%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Inovio Pharmaceuticals, Inc. (INO)
Category
Healthcare
Operating Margin for Inovio Pharmaceuticals, Inc. (INO)
Operating Margin as of November 2026 TTM: 0.00%
According to Inovio Pharmaceuticals, Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of -132,871.32%.
Operating Margin history for Inovio Pharmaceuticals, Inc. from 2000 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | -100.00% |
| 2025 | -132,871.32% | 157.42% |
| 2024 | -51,616.91% | 198.36% |
| 2023 | -17,300.28% | 563.52% |
| 2022 | -2,607.35% | -84.64% |
| 2021 | -16,972.34% | 913.73% |
| 2020 | -1,674.25% | -38.04% |
| 2019 | -2,702.10% | 775.37% |
| 2018 | -308.68% | 55.81% |
| 2017 | -198.11% | -8.09% |
| 2016 | -215.55% | 155.09% |
| 2015 | -84.50% | -77.63% |
| 2014 | -377.71% | 160.27% |
| 2013 | -145.12% | -74.56% |
| 2012 | -570.42% | 158.21% |
| 2011 | -220.91% | -29.37% |
| 2010 | -312.79% | 104.38% |
| 2009 | -153.04% | -76.50% |
| 2008 | -651.14% | 96.91% |
| 2007 | -330.68% | -14.07% |
| 2006 | -384.82% | 35.68% |
| 2005 | -283.63% | -71.24% |
| 2004 | -986.27% | -88.03% |
| 2003 | -8,237.11% | 163.04% |
| 2002 | -3,131.53% | 2,400.82% |
| 2001 | -125.22% | -33.32% |
| 2000 | -187.79% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Inovio Pharmaceuticals, Inc.'s operating margin
What was Inovio Pharmaceuticals, Inc.'s operating margin in 2025?
In 2025, Inovio Pharmaceuticals, Inc.'s operating margin was -132,871.32%, compared with -51,616.91% in 2024.
How has Inovio Pharmaceuticals, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Inovio Pharmaceuticals, Inc.'s operating margin was highest in 2020 (-1,674.25%) and lowest in 2025 (-132,871.32%).
How does Inovio Pharmaceuticals, Inc.'s operating margin compare with similar companies?
Inovio Pharmaceuticals, Inc.'s operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.